Aging-related bone loss and osteoporosis affect millions of people worldwide. Chronic inflammation associated with aging promotes bone resorption and impairs bone formation. Here we show that Wnt4 attenuates bone loss in osteoporosis and skeletal aging mouse models by inhibiting nuclear factor-kB (NF-kB) via noncanonical Wnt signaling. Transgenic mice expressing Wnt4 from osteoblasts were significantly protected from bone loss and chronic inflammation induced by ovariectomy, tumor necrosis factor or natural aging. In addition to promoting bone formation, Wnt4 inhibited osteoclast formation and bone resorption. Mechanistically, Wnt4 inhibited NF-kB activation mediated by transforming growth factor-b-activated kinase-1 (Tak1) in macrophages and osteoclast precursors independently of b-catenin. Moreover, recombinant Wnt4 alleviated bone loss and inflammation by inhibiting NF-kB in vivo in mouse models of bone disease. Given its dual role in promoting bone formation and inhibiting bone resorption, our results suggest that Wnt4 signaling could be an attractive therapeutic target for treating osteoporosis and preventing skeletal aging.
Normal bone remodeling maintains constant bone mass by an orchestrated balance between the destruction of preexisting bone by osteoclasts and rebuilding it by osteoblasts 1, 2 . Aging is associated with substantial changes to the skeletal system that are characterized by structural alterations including reduction in trabecular bone volume, density and strength 3, 4 , as well as a shift in tissue microenvironment with increasing proinflammatory cytokine levels in bone marrow and the serum [5] [6] [7] [8] . Advancing age is also a critical risk factor for osteoporosis, which is the most common metabolic bone disease and a leading cause of morbidity and mortality in our aging population [9] [10] [11] . In osteoporosis, bone homeostasis is dysregulated by hormonal deficiency and aging, leading to increased bone turnover with enhanced bone formation and even greater rates of bone resorption, resulting in a net bone loss. Skeletal aging also manifests through other scenarios of abnormal bone remodeling, such as reduced formation and accelerated resorption in inflammatory bone diseases and low bone turnover in physiological aging. Both bone formation and resorption are regulated on the local level by factors secreted by bone cells, as well as on the systemic level by hormones 4, [11] [12] [13] [14] .
Chronic inflammation has been found to be associated with osteoporosis and aging-related bone loss 1, 6, 7 . In general, the transcription factor NF-κB is activated during inflammatory processes 15 . Growing evidence suggests that NF-κB plays an important role in aging-related disorders, including aging-related bone loss and osteoporosis [16] [17] [18] [19] .
Inhibition of NF-κB has been shown to attenuate osteoporosis and arthritis 20, 21 . We previously reported that NF-κB activation inhibits bone formation in estrogen deficiency-induced bone loss 22 . Thus, targeting NF-κB may allow both inhibition of bone resorption and promotion of bone formation.
The Wnt family proteins are key regulators in growth and development, stem cell self-renewal and cancer development 23, 24 . Wnt signaling has also emerged as a critical player in bone homeostasis 25, 26 . The 19 Wnt family proteins are divided into canonical and noncanonical ligands based on their dependence on transduction through β-catenin [27] [28] [29] . Although there have been a few studies elucidating the role of noncanonical Wnt signaling in osteoblast differentiation [30] [31] [32] [33] , little is known regarding how this signaling pathway affects osteoclast formation. Signaling between Wnt5a and receptor tyrosine kinase-like orphan receptor-2 (Ror2) has been found to promote osteoclastogenesis by activating the Wnt-c-Jun terminal kinase (JNK) pathway 32 . Previously, we found that Wnt4, a prototypical ligand for the noncanonical Wnt pathway, is able to promote osteoblast differentiation of mesenchymal stem cells (MSCs) 33 . To further explore the therapeutic potential of Wnt4, we generated transgenic mice that express Wnt4 in osteoblasts. We confirmed that Wnt4 could enhance bone formation in vivo, but we also found that Wnt4 could inhibit osteoclast formation and inflammation in vivo, thus attenuating bone loss and osteoporosis. Together with our previously published findings, our 1 0 1 0 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine results suggest that Wnt4 signaling may represent an attractive target to treat bone loss as it promotes osteoblast generation and inhibits osteoclast formation.
RESULTS

Wnt4 promotes bone formation in vivo
To explore whether Wnt4 promoted bone formation in vivo, we generated transgenic mice in which Wnt4 is driven by the mouse 2.3-kb type 1 collagen (Col2.3) promoter (OB-Wnt4 mice). The Col2.3 promoter contains a 2.3-kb DNA fragment upstream of the transcription start site of the Col1a1 gene 34 and has been shown to drive gene expression specifically in differentiated osteoblasts 35 . The fragments of the Wnt4 transgene were microinjected into C57BL/6 × SJL mouse oocytes, and the oocytes were surgically transferred to pseudopregnant C57BL/6 dams. Seven of the ten potential founders screened displayed strong expression of the transgene (Supplementary Fig. 1a ), thus allowing establishment of two separate transgenic mouse lines (TG1 and TG7). Whereas hemagglutinin-tagged transgenic Wnt4 was undetectable in primary calvarial cells from wild-type (WT) C57BL/6 mice, Wnt4 in calvarial cells from TG1 and TG7 mouse lines was induced as the cells differentiated into osteoblasts in osteogenic medium ( Fig. 1a) . RT-PCR confirmed that Wnt4 transgene mRNA was expressed in bone tissue but not in brain, heart, kidney, liver, spleen or muscle using the TG7 line ( Fig. 1b) .
Next, we investigated whether Wnt4 could enhance bone formation in vivo using the TG7 line. Of note, both lines of OB-Wnt4 mice had a phenotypically normal skeleton at birth (data not shown). Microcomputed tomography (µCT) analysis of the secondary spongiosa of the distal femur metaphysis revealed that the bone mineral density (BMD) of OB-Wnt4 mice was significantly higher compared to WT littermates at 1, 2 and 3 months of age ( Fig. 1c,d) . Similarly, the bone volume/tissue volume ratio (BV/TV) was significantly higher in OB-Wnt4 mice compared to WT mice ( Fig. 1e) , consistent with the greater amount of trabecular bones shown in H&E staining (Fig. 1f) . Histomorphometric analysis revealed mildly higher osteoblast counts in 3-month-old OB-Wnt4 mice compared to WT mice ( Fig. 1g) . To further confirm whether the increased BMD was due to enhanced osteoblast function, we performed dynamic histomorphometric analysis over a 7-d period using calcein labeling 22 and found that the bone formation rate (BFR) in 3-month-old OB-Wnt4 mice was significantly higher compared to WT mice ( Fig. 1h) . Similarly, characterization of the TG1 mouse line also confirmed that Wnt4 enhanced bone formation in vivo, ruling out variations due to mouse strains ( Supplementary Fig. 1b,c) .
To examine whether Wnt4 enhanced osteoblastic activity in a cellautonomous manner, we isolated bone marrow MSCs from femurs of OB-Wnt4 mice and WT mice. Primary MSCs from OB-Wnt4 mice demonstrated enhanced osteogenic potential, as evidenced by alkaline phosphatase and Alizarin red staining, when cells were induced by osteogenic medium (Fig. 1i,j) . Furthermore, real-time RT-PCR showed greater mRNA expression of the master osteogenic transcription factors Runx2 and Sp7 (Supplementary Fig. 1d,e ), as well as the mineralization markers Ibsp and Bglap ( Supplementary  Fig. 1f,g) , in differentiated osteoblasts from OB-Wnt4 mice compared with WT mice.
Wnt4 prevents estrogen deficiency-induced bone loss
To mimic the molecular pathogenesis of osteoporotic bone loss, mouse ovariectomy (OVX) has been widely used as an animal model of this condition 6, 22, 36 . We performed OVX or sham operation on 3-month-old WT and OB-Wnt4 mice, followed by µCT analysis of femurs from these mice. We found noticeable trabecular bone loss in WT mice compared to sham controls 2 months after OVX. In contrast, bone loss was markedly lower in OB-Wnt4 mice after OVX compared to WT mice ( Fig. 2a) . Quantitative measurements showed that whereas 47% of BMD and 48% of BV/TV were lost in WT mice after OVX, only 27% of BMD and 24% of BV/TV were lost in OB-Wnt4 mice ( Fig. 2b) . Following OVX, BFR was higher in WT mice to compensate for the accelerated bone resorption, whereas in OB-Wnt4 mice, osteoblastic activity was further enhanced (Fig. 2c) . Similarly, toluidine blue staining revealed significantly higher osteoblast number and osteoblast surface in OB-Wnt4 as compared to WT mice in both OVX and sham groups (Fig. 2d) .
In contrast, we observed lower osteoclast number and surface in OB-Wnt4 mice compared to WT mice in both OVX and sham groups ( Fig. 2e,f) . We also performed ELISA to assess the serum markers of bone turnover. The serum concentrations of osteocalcin, a marker of bone formation, were significantly higher in OB-Wnt4 mice compared to WT mice after OVX ( Fig. 2g) . In contrast, OVX induced higher serum concentrations of Trap5b, a marker of bone resorption 37 , in WT but not in OB-Wnt4 mice ( Fig. 2h) .
Studies have implicated proinflammatory cytokines, including tumor necrosis factor (Tnf) and interleukin-6 (Il-6), as important mediators of accelerated bone loss in osteoporosis 38, 39 . Consistent with this, OVX induced an elevation in serum concentrations of Tnf and Il-6 in WT mice, but such induction was suppressed in OB-Wnt4 mice ( Fig. 2i) . Immunostaining of activated p65 in femur sections revealed enhanced NF-κB activity in osteoclasts and bone marrow cells surrounding trabecular bones following OVX. In contrast, the NF-κB activation by OVX was significantly less pronounced in OB-Wnt4 mice ( Fig. 2j) . To further confirm the inhibition of NF-κB by Wnt4 in vivo, we immunostained NF-κB-dependent targets, including Tnf, cycloxygenase-2 (Cox-2) and matrix metallopeptidase-9 (Mmp9). Consistent with activated p65 staining, we found that Wnt4 also potently reduced the expression of Tnf, Cox-2 and Mmp9 induced by OVX in vivo (Supplementary Fig. 2a-c) .
Wnt4 inhibits TNF-induced inflammatory bone loss TNF potently induces inflammation by activating NF-κB. Transgenic mice overexpressing human TNF (TNFtg) develop systemic bone loss and osteoporosis in addition to erosive arthritis due to a higher degree of osteoclastogenesis and inhibition of bone formation [40] [41] [42] . To further determine whether Wnt4 could directly inhibit inflammationassociated bone loss, we bred TNFtg mice with OB-Wnt4 mice (TNFtg/ OB-Wnt4 mice). There was severe paw and joint swelling, often associated with joint deviation, in 1-year-old TNFtg mice. We also performed µCT and histological analyses, which revealed extensive joint cartilage a b 1 0 1 2 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine destruction and bone erosions due to invasion of inflammatory cells ( Supplementary Fig. 3a-e ). In contrast, there was significantly less joint swelling, bone erosion and inflammation in TNFtg/OB-Wnt4 mice than in TNFtg mice of comparable age ( Supplementary Fig. 3a-e ). Consistent with previous studies, µCT analysis revealed systemic bone loss suffered by 1-year-old TNFtg mice compared with WT mice. However, bone loss in femurs from 1-year-old TNFtg/OB-Wnt4 mice was markedly mitigated (Fig. 3a) . Quantitative measurements revealed that whereas 31% of BMD and 68% of BV/TV were lost in TNFtg mice compared to WT mice, only 18% of BMD and 28% of BV/TV were lost in TNFtg/OB-Wnt4 mice (Fig. 3b) . As the reduced bone loss could be due to either higher bone formation or lower bone resorption (or both), we examined the effect of Wnt4 on both components of bone homeostasis. The lower degree of BFR and mineral apposition rate (MAR) in TNFtg mice compared to WT mice were alleviated in TNFtg/OB-Wnt4 mice ( Fig. 3c) . Consistent with this finding, histomorphometric analysis also showed 24% greater osteoblast counts in TNFtg/OB-Wnt4 than in TNFtg mice ( Fig. 3d) .
As it has been shown that osteoclastogenesis and bone resorption were enhanced in TNFtg mice [40] [41] [42] , we next examined the effect of Wnt4 on accelerated bone resorption in TNFtg mice. Both histomorphometric analysis and tartrate-resistant acid phosphatase (TRAP) staining revealed that whereas osteoclast activity was higher in TNFtg mice compared to WT controls, it was significantly lower in TNFtg/ OB-Wnt4 mice (Fig. 3e,f) . Consistent with this, the serum concentrations of osteocalcin were significantly lower in TNFtg mice than in TNFtg/OB-Wnt4 mice (Fig. 3g) . On the other hand, the serum concentrations of Trap5b were significantly higher in TNFtg mice than in TNFtg/OB-Wnt4 mice (Fig. 3h) .
We observed that the serum Il-6 concentration in TNFtg/OB-Wnt4 mice was only 55% of that in TNFtg mice (Fig. 3i) . As TNF is a potent activator of NF-κB that is associated with osteoporosis and skeletal aging 16, 22, 43 , we next examined whether Wnt4 inhibited TNF-induced NF-κB activation in the TNFtg/OB-Wnt4 mice. Immunostaining of active p65 revealed markedly enhanced NF-κB activity in the proximity of trabecular bones in TNFtg mice, whereas NF-κB staining was significantly reduced in TNFtg/OB-Wnt4 mice (Fig. 3j) . Moreover, Wnt4 also inhibited the expression of Cox-2 and Mmp9 in osteoclasts and bone marrow cells induced by TNF in vivo (Supplementary Fig. 3f,g) .
Wnt4 prevents skeletal aging and bone loss
Aging creates a proinflammatory environment with elevated levels of cytokines that contribute to various chronic diseases including osteoporosis and osteopenia 4, [44] [45] [46] . We further examined whether Wnt4 could protect against natural aging-mediated bone loss or osteopenia. We performed µCT analysis in WT mice and found that there was a gradual loss of trabecular bone mass with advancing age from 6 to 24 months (Fig. 4a) . Further quantitative analysis showed that the most dramatic loss occurred between 6 and 12 months of age, when average BMD dropped 42.7% and BV/TV dropped 67.1%. However, the reductions were significantly less in OB-Wnt4 mice, with a 32.0% decrease in BMD and a 41.9% decrease in BV/TV (Fig. 4b) . Histological staining also confirmed that aged OB-Wnt4 mice lost less trabecular bone than aged WT mice ( Fig. 4c) . Of note, using RT-PCR, we confirmed that Wnt4 transgene mRNA in bone tissues was still expressed in aged OB-Wnt4 mice, in spite of a noticeable decline in mRNA levels with age ( Supplementary Fig. 4a,b) .
Immunostaining also demonstrated that Wnt4 was strongly expressed in aged OB-Wnt4 mice but weakly expressed in osteoblasts in aged WT mice (Supplementary Fig. 4c ).
Morphometric measurements for osteoblasts, as well as serum osteocalcin concentrations, also remained significantly higher in OB-Wnt4 mice than in WT mice across all ages (Fig. 4d,e ). Osteoclast number was higher in aged 18-month-old WT mice compared to 3-month-old mice (Fig. 4f) ; however, in aged OB-Wnt4 mice, osteoclast counts were significantly lower compared to aged WT mice (Fig. 4f) . Notably, whereas serum Trap5b concentrations were not significantly different between OB-Wnt4 and WT mice at 3 months of age, they were drastically higher at 18 or 24 months in WT mice but not in OB-Wnt4 mice (Fig. 4g) . Furthermore, serum concentrations of Il-6 also showed a similar trend (Fig. 4h) . Finally, we examined whether natural aging-associated NF-κB activation was suppressed by Wnt4. Whereas immunostaining of active p65 revealed intense NF-κB activity in the vicinity of trabecular bones in aged WT mice, NF-κB activity appeared less prevalent in aged OB-Wnt4 mice (Fig. 4i,j) . Consistent with this, the expression of Tnf, Cox-2 and Mmp9 was markedly weaker in aged OB-Wnt4 mice compared with aged WT mice (Supplementary Fig. 4d ).
Wnt4 inhibits Tak1-NF-kB signaling
Our in vivo results suggest that Wnt4 secreted by osteoblasts may inhibit osteoclast formation and bone resorption in a paracrine fashion. To confirm our hypothesis, we examined whether Wnt4 could directly inhibit osteoclast differentiation using recombinant Wnt4 (rWnt4) protein. As evidenced by TRAP staining, rWnt4 protein significantly inhibited osteoclast differentiation of primary bone marrow macrophages induced by receptor activator of NF-κB ligand (Rankl; Supplementary Fig. 5a) . Similarly, the osteoclast-like differentiation of RAW264.7 cells induced by Rankl was also attenuated by Wnt4 (Supplementary Fig. 5b ). Real-time RT-PCR confirmed that rWnt4 inhibited the expression of osteoclast marker genes, including Acp5, Mmp9 and Ctsk, induced by Rankl in bone marrow macrophages and RAW264.7 cells (Supplementary Fig. 5c,d) . As Wnt4 inhibited the expression of NF-κB target genes in vivo, we also examined whether rWnt4 inhibited the expression of NF-κB target genes induced by Rankl. Real-time RT-PCR revealed that rWnt4 potently inhibited induction of the NF-κB-dependent genes Il6 and Birc3 by Rankl in bone marrow macrophages (Supplementary Fig. 5e ) and in RAW264.7 cells (Supplementary Fig. 5f ). Consistent with our findings from immunostaining in vivo, rWnt4 also significantly Fig. 5g ).
To further elucidate the molecular mechanism by which Wnt4 inhibited NF-κB and osteoclastogenesis, we examined each key step of NF-κB activation induced by Rankl. Activation of the Rank receptor leads to association of its cytoplasmic domain with Tnf receptor-associated factor-6 (Traf6), which is essential in osteoclast differentiation 47, 48 . Traf6 forms a complex with Tak1 and Tak1binding protein-2 (Tab2), leading to phosphorylation and activation of Tak1 (ref. 49 ). In canonical NF-κB signaling, Tak1 then phosphorylates IκB kinase (IKK) complex and thereby initiates degradation of IκBα, followed by phosphorylation and nuclear translocation of p65 to activate downstream target genes 49 . Western blot analysis revealed that rWnt4 potently inhibited Tak1 phosphorylation, as well as the subsequent phosphorylation of p65 and the phosphorylation and degradation of IκBα induced by Rankl (Fig. 5a) . Furthermore, rWnt4 also suppressed Rankl-induced nuclear translocation of p65 (Fig. 5b) . Moreover, rWnt4 inhibited NF-κB-dependent transcription, as determined by the NF-κB-dependent luciferase reporter assay (Fig. 5c) .
Because Tak1 also forms a complex with Nemo-like kinase (Nlk) and Tab2 in noncanonical Wnt signaling 27, 50 , we hypothesized that rWnt4 stimulation may interfere with the formation of the Traf6-Tak1-Tab2 complex induced by Rankl. Immunoprecipitation using antibodies specific to Traf6 revealed that Rankl induced the formation of the Traf6-Tak1-Tab2 complex (Fig. 5d) . However, addition of rWnt4 drastically inhibited the formation of the Traf6-Tak1-Tab2 complex (Fig. 5d) . In contrast, we observed that rWnt4 stimulation induced the formation of the Tak1-Tab2-Nlk complex, and the addition of Rankl partially reduced the formation of the Tak1-Tab2-Nlk complex (Fig. 5d) . As Traf6-Tak1 signaling also activates p38 mitogen-activated protein kinase, Jnk and extracellular signalregulated kinase (Erk), we examined whether rWnt4 inhibited the activation of p38, Jnk and Erk induced by Rankl. We found that rWnt4 partially inhibited the phosphorylation of Erk, p38 and Jnk induced by Rankl (Supplementary Fig. 5h) .
As the nuclear factor of associated T cells-c1 (Nfatc1) is the key transcription factor for osteoclastogenesis 51 , we examined the effect of rWnt4 treatment on its expression following Rankl stimulation in bone marrow macrophages. We found that the induction of Nfatc1 by Rankl was repressed by rWnt4 ( Fig. 5e) . Previously, it has been shown that activation of NF-κB induces expression of Nfatc1, which in turn activates osteoclast differentiation 52 . Both NF-κB and NFAT consensus binding sites exist at the Nfatc1 promoter. Upon induction by Rankl, p65 is recruited to the Nfatc1 promoter to activate its transcription, and subsequently, the newly generated Nfatc1 can autoamplify itself 52 . Chromatin immunoprecipitation (ChIP) assays revealed that rWnt4 significantly suppressed Rankl-induced p65 binding to the Nfatc1 promoter ( Fig. 5f) . Consequently, rWnt4 also potently reduced Nfatc1 binding at its own promoter induced by Rankl (Fig. 5g) .
We previously found that Wnt4 activates noncanonical Wnt signaling in MSCs 33 , but Wnt4 might also stimulate canonical Wnt signaling by stabilizing β-catenin. To rule out this possibility, we examined whether rWnt4 protein increased the levels of cytosolic and nuclear β-catenin in bone marrow macrophages. Subcellular fractionation revealed that whereas rWnt3a increased the levels of cytosolic and nuclear β-catenin, rWnt4 did not induce the accumulation of β-catenin (Fig. 5h) . Moreover, we also examined whether rWnt4 induced β-catenin-dependent transcription using a TOPflash luciferase reporter. rWnt3a, but not rWnt4, significantly activated the luciferase reporter in bone marrow macrophages (Fig. 5i) . In addition, two well-known Wnt-β-catenin pathway target genes, Axin2 and Dkk1, were induced by rWnt3a but not by rWnt4 ( Fig. 5j) .
rWnt4 inhibits OVX-induced bone loss
To explore whether Wnt4 can be used clinically, we first tested whether rWnt4 prevents bone loss by inhibiting NF-κB in an OVX mouse model. We ovariectomized 3-month-old mice and immediately began intraperitoneal administration of rWnt4 once a day for 3 weeks. We then performed µCT analysis, which showed that whereas mice that underwent OVX suffered marked loss in trabecular BMD and BV/TV 1 month after OVX, mice injected with rWnt4 had significantly less bone loss (Supplementary Fig. 6a-c) . Histological analysis also confirmed that rWnt4 significantly inhibited trabecular bone loss induced by OVX (Supplementary Fig. 6e-g) . Moreover, rWnt4 also reduced serum Trap5b levels (Supplementary Fig. 6h ).
Immunostaining showed that rWnt4 inhibited NF-κB activity in osteoclasts and adjacent inflammatory cells upon OVX ( Supplementary  Fig. 6i) . Consistent with this, we found that serum levels of Il-6 and Tnf induced by OVX were significantly reduced by rWnt4 (Supplementary Fig. 6j) .
To further evaluate the therapeutic value of rWnt4, we examined whether rWnt4 could reverse established bone loss in mice induced by OVX. We first performed OVX on 3-month-old mice and waited for 1 month to establish bone loss. We then administered rWnt4 or the vehicle control (PBS) to mice for 1 month. We performed µCT analysis and found that rWnt4 treatment in the OVX group was associated with significantly higher degrees of BMD and BV/TV compared to PBS-treated OVX mice (Fig. 6a,b) . Histological staining confirmed that rWnt4 treatment was associated with lower trabecular bone loss induced by OVX compared to PBS-treated OVX mice (Fig. 6c) . Histomorphometric analysis also showed that the rWnt4-treated OVX mice had significantly higher osteoblast counts and lower osteoclast numbers compared to PBS-treated OVX mice ( Fig. 6d-f) . Consistent with these results, rWnt4 treatment of OVX mice was associated with lower serum Trap5b concentrations and higher serum osteocalcin concentrations versus those treated with PBS ( Fig. 6g,h) . Immunostaining revealed that rWnt4 potently inhibited NF-κB activity in osteoclasts and adjacent bone marrow cells (Fig. 6i) , as well as the expression of Tnf, Cox-2 and Mmp9 ( Supplementary  Fig. 7) . We found that rWnt4 treatment of OVX mice was also significantly associated with lower serum concentrations of Il-6 and Tnf than those treated with PBS ( Fig. 6j) .
DISCUSSION
Using three different but complementary animal models, we demonstrated that Wnt4 could reduce OVX-, inflammation-and aging-related bone loss by inhibiting NF-κB, revealing a previously uncharacterized cross-talk between noncanonical Wnt signaling and NF-κB. Gain-or loss-of-function mutations of Wnt signaling components have been identified in a variety of human bone disorders 26, 53, 54 .
Recently, Wnt5a has been found to enhance osteoclast formation and bone resorption by activating the noncanonical JNK signaling pathway. Wnt5a enhanced osteoclastogenesis induced by Rankl through the Ror2 receptor 32 , suggesting that targeting Wnt5a may prevent bone erosion in arthritis. However, Wnt5a-haploinsufficient mice had a bone-loss phenotype with increased adipogenesis in bone marrow 50 . Thus, Wnt5a might not be an ideal therapeutic agent for arthritis and 1 0 1 6 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine metabolic bone loss. On the contrary, we found that Wnt4 inhibited osteoclastogenesis and bone resorption in vitro and in vivo by inhibiting NF-κB while promoting bone formation, thereby holding more promise as a potential therapeutic agent for preventing skeletal aging, osteoporosis and arthritis compared to Wnt5a. Various Wnt ligands can elicit different responses depending on their receptors and cell contexts. Wnt5a acts via Ror2 to enhance the expression of Rank in osteoclast precursors by stimulating activator protein-1 and promotes Rankl-induced osteoclast formation 32 . Notably, we found that Wnt4 suppresses Tak1 activation induced by Rankl, resulting in the inhibition of IKK-NF-κB signaling activation in macrophages and osteoclast precursors. Although Tak1 plays a role in noncanonical Wnt signaling by interacting with Nlk 50 , it also modulates canonical Wnt signaling 55, 56 . The definitive role of Tak1 in both canonical and noncanonical signaling might depend on cell context and individual Wnt ligands. Our results suggest that Wnt4 might activate its receptors to promote Tak1-mediated noncanonical Wnt signaling in osteoclasts and subsequently sequester Tak1 from effectively binding with Traf6 to induce the NF-κB signaling cascade. Although we showed that Wnt4 promoted Tak1 binding to Nlk, it is possible that Wnt4 might also promote the interaction between Tak1 and the Wnt signaling components, as it has been reported that Ror2 interacts with Tak1 (ref. 55) .
Most drugs currently used for osteoporosis are inhibitors of bone resorption, but they cannot restore the substantial bone loss that has already occurred at the time of diagnosis. Therefore, a better treatment module for osteoporosis would not only block bone catabolism but also promote bone anabolism while controlling local inflammation [6] [7] [8] 11 . Multiple Wnt proteins, including Wnt4, have been detected in bone tissues or bone marrow 54, 57, 58 . Although the inhibition of aging-associated bone loss and inflammation is mainly based on transgenic overexpression of Wnt4, multiple noncanonical Wnt ligands, including Wnt4, Wnt6, Wnt11 and Wnt16, are expressed in osteoprogenitors 57, 58 . They may collectively protect against agingassociated bone loss and inflammation. Notably, we show that rWnt4 proteins effectively inhibit OVX-induced bone loss by inhibiting NF-κB. Although canonical Wnt proteins have potential therapeutic value for treating osteoporosis by promoting bone formation, the constitutive activation of β-catenin might also increase the risk for cancer development that is associated with aging 23, 24 . As Wnt4 does not activate β-catenin in either osteoblasts or osteoclasts, and by inhibiting NF-κB, our results suggest that rWnt4 may be a better, and perhaps safer, therapeutic agent for preventing skeletal aging-related bone loss and treating inflammatory bone diseases.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
We performed ChIP assays using a ChIP assay kit (Upstate, USA) following the manufacturer's recommendation. Briefly, we incubated cells with a dimethyl 3,3′ dithiobispropionimidate-HCl (Pierce) solution (5 mM) for 10 min at room temperature, followed by formaldehyde treatment for 15 min in a 37 °C water bath. For each ChIP reaction, we used 2 × 10 6 cells. We then quantified resulting precipitated DNA samples with realtime PCR and expressed data as the percentage of input DNA. Antibodies for ChIP assays were purchased from the following commercial sources: polyclonal anti-p65 (Millipore); polyclonal anti-NFATc1 (Santa Cruz). The primers for Nfatc1 are: forward, 5′-CTGTGTTCCCACATGTCCTC-3′; reverse, 5′-GCGACTGCAGTGTGTTCTTT-3′. 9 kb downstream for Nfatc1 are: forward, 5′-CTGGCACCAAAGTTGAGAGA-3′; reverse, 5′-GATG GCTCTACCTGCACAGA -3′. OVX, bone histomorphometry and scoring of arthritic joint swelling. We performed OVX or sham operation on 3-month-old female WT and OB-Wnt4 mice under isofluorane anesthesia. For the preventive model, rWnt4 proteins (8 µg kg −1 ) were intraperitoneally injected daily for 3 weeks immediately after the surgery. For dual labeling, mice received intraperitoneal injection of calcein (0.5 mg per mouse, Sigma-Aldrich) 10 and 3 d before euthanasia. Mice were euthanized 1 month after OVX. For the therapeutic model, we first performed OVX on 3-month-old mice and waited for 1 month to establish bone loss. Mice received intraperitoneal injection of rWnt4 (20 µg kg −1 ) or vehicle control daily for 1 month before collection of bone samples. Eight to twelve mice were used in each group.
Following euthanasia, we fixed right femurs in 70% ethanol for 48 h and embedded in methyl methacrylate. 8-µm longitudinal sections were either stained with toluidine blue for osteoblast count or examined under fluorescent microscope to evaluate BFR and MAR as described previously 22 . We fixed left femurs in 10% formaldehyde and embedded them in paraffin for preparation in 5-µm-thick sections. We analyzed osteoclast parameters after TRAP staining as described. For all brightfield and fluorescent microscopy analysis, we used Olympus-IX51 inverted microscope with SPOT advanced 4.0 and CellSens software.
We scored the swelling of hindpaws on 1-year-old TNFtg and TNFtg/OB-Wnt4 mice on a scale of 0 to 3, as previously described 60,61 : 1 = mild arthritis (mild swelling of joint and paw); 2 = moderate arthritis (severe swelling and joint deviation); and 3 = severe arthritis (ankylosis detected upon flexion). We used histological sections of hindpaw and ankle joints to examine the tibiotalar and interdigital joints and performed µCT imaging to further evaluate bone erosion and destruction of joint space associated with arthritis.
Immunostaining and mCT analysis of mice. We extracted femurs from euthanized mice and fixed them in 10% neutral buffered formalin for 24 h. For µCT scanning, the specimens were fitted in a cylindrical sample holder (20.5 mm in diameter) with the long axis of the femur perpendicular to the X-ray source. We used a Scanco µCT40 scanner (Scanco Medical) set to 55 kVp and 70 µA. The bone volume (mm 3 ) over tissue volume and bone mineral density in the region of interest were measured directly with µCT Evaluation Program V4.4A (Scanco Medical). We defined the regions of interest as the areas between 0.3 mm and 0.4 mm proximal to the growth plate in the distal femurs in order to include the secondary trabecular spongiosa. A threshold of 250 was used for evaluation of all scans 22 . For visualization, we imported the segmented data and reconstructed them as a three-dimensional image displayed in µCT Ray V3.0 (Scanco Medical).
After scanning, we decalcified the specimens and sectioned them for staining as previously described 22 . Antibodies used included rabbit polyclonal anti-NLS-p65 (600-401-271; 1:200; Rockland), rabbit polyclonal anti-Mmp9 (38898; 1:500; Abcam), rabbit polyclonal anti-Tnf (34674, 1:200; Abcam), and rabbit polyclonal anti-Cox2 (15191, 1:400, Abcam). For quantification of p65 positive staining, we selected at least ten images from each section per femur, measured the integral optical density (IOD) of nuclear-stained p65 using the Image Pro Plus 6.0 software (MediaCybernetics). We normalized the IOD by stained area and presented the data as reported previously 62 .
Statistical analyses. Numerical data and histograms were expressed as the mean ± s.d. Two-tailed Student's t-test was performed between two groups and a difference was considered statistically significant with P < 0.05.
